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Abstract
Background: Over the last few decades, new synthetic 
insulin analogues have been developed. Their measure­
ment is of prime importance in the investigation of 
hypoglycaemia, but their quantification is hampered by 
variable cross­reactivity with many insulin assays. For 
clinical analysis, it has now become essential to know the 
potential cross­reactivity of analogues of interest.
Methods: In this work, we performed an extensive study 
of insulin analogue cross­reactivity using numerous 
human insulin immunoassays. We investigated the cross­
reactivity of five analogues (lispro, aspart, glulisine, glar­
gine, detemir) and two glargine metabolites (M1 and M2) 
with 16 commercial human insulin immunoassays as a 
function of concentration.
Results: The cross­reactivity values for insulin analogues 
or glargine metabolites ranged from 0% to 264%. Four 
assays were more specific to human insulin, resulting in 
negligible cross­reactivity with the analogues. However, 
none of the 16 assays was completely free of cross­reac­
tivity with analogues or metabolites. The results show that 
analogue cross­reactivity, which varies to a large degree, 
is far from negligible, and should not be overlooked in 
clinical investigations.
Conclusions: This study has established the cross­reac­
tivity of five insulin analogues and two glargine metabo­
lites using 16 immunoassays to facilitate the choice of 
the immunoassay(s) and to provide sensitive and specific 
analyses in clinical routine or investigation.
Keywords: cross­reactivity; human insulin; immunoas­
says; insulin analogues.
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Introduction
Measurement of insulin concentration is useful to inves­
tigate hypoglycaemia, β­cell function, insulin resistance, 
insulinoma, and to determine the pathogenesis of type 1 
and 2 diabetes. Even if, owing to analytical pitfalls [1, 2], 
commercially available human insulin assays are still 
awaiting standardisation, they are currently used in clini­
cal investigation [2–5]. Insulin is synthesised in the β­cells 
of the islets of Langerhans as a proinsulin precursor, 
which is processed to form insulin and C­peptide. Both are 
secreted in equimolar amounts into the portal circulation. 
Thus, recombinant insulin administration can be sus­
pected when insulin and C­peptide levels are discordant: 
a suppressed or undetectable C­peptide value associated 
with a normal­to­elevated insulin value is in favour of syn­
thetic insulin administration taking into account their dis­
tinct half­life. When pharmaceutical recombinant insulin, 
with a sequence identical to that of human insulin, is 
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administered, human insulin assays are usually coupled 
with C­peptide measurements to distinguish exogenous 
synthetic insulin injections from physiological insulin.
Owing to the limiting pharmacokinetic and pharma­
codynamic features of the recombinant human insulin 
sequence, rapid­ and/or long­acting analogues have been 
used since 1996 [6]. These new synthetic insulin analogues 
have complicated the detection of synthetic insulin. Thevis 
et  al. have largely described mass spectrometry­based 
methods for insulin analogue assessment [7–11]. However, 
these methods are highly technically demanding. They 
have been described for anti­doping test purposes and are 
not widespread. Furthermore, as preliminary immuno­
extraction is required prior to chromatographic and mass 
spectrometric analysis, assay performances are limited to 
detection without quantification.
Human insulin immunoassays are easy to perform, 
but clinicians and clinical chemists must be aware that 
possible cross­reactivity has already been highlighted 
between endogenous or exogenous standard insulin and 
analogues in sera assays [12–14]. Failing that, misdiagno­
sis can occur as described in the observation by Krull et al. 
[15]. In that case, hypoglycaemia was initially associated 
to non­measurable plasma insulin levels (Elecsys, Roche 
Diagnostics), which could be attributed to deficiencies in 
counter­regulatory hormones such as cortisol or growth 
hormone, severe hepatic or renal failure or large non­islet 
tumours producing IGF­2. However, a second insulin assay 
performed with Advia Centaur® (Siemens), yielded high 
“insulin” levels due to significant cross­reactivity with 
insulin glargine and lispro. A secret insulin administra­
tion, responsible for the factitious hypoglycaemia, was 
thus detected [15]. In another case report, despite a serum 
insulin concentration within the reference range, hypo­
glycaemia was observed. The surreptitious association of 
human insulin with glargine and insulin aspart escaped 
detection owing to low cross­reactivity between the ana­
logues and human insulin in the insulin assays [16]. Lack 
of control of cross­reactivity of insulin analogues leads to 
misdiagnosis with clearly established clinical impact. As a 
consequence, different studies focused on the determina­
tion of the cross­reactivity of various analogues using one 
particular insulin assay [14, 17–22]. Those works showed, 
for example, that the Architect insulin assay (Abbott Labo­
ratories) had a low cross­reactivity to the insulin analogue 
aspart, whereas it detected lispro and glargine, in con­
centrations as high as the theoretical concentrations [12]. 
More recently, Vieira et al. (2007) showed cross­reactivity 
between insulin glargine and regular human insulin in an 
immunofluorimetric assay provided by PerkinElmer [14]. 
However, from a practical point of view, it is essential to 
define the technique (or combination of techniques) that 
will highlight the presence or absence of insulin ana­
logues. This involves extending such studies to a wide 
range of immunoassays, an undertaking initiated by 
Owen in 2004 [13].
To address this situation, in the present study, we set 
about an extensive evaluation of the cross­reactivity of 
rapid­ (lispro, glulisine, aspart) and long­acting (detemir, 
glargine and its two metabolites: M1, M2) analogues 
with numerous and frequently used commercial assays. 
A comparison of 16 human insulin immunoassays has 
been performed for both insulin analogues and glargine 
metabolites. This study includes glulisine, the latest addi­
tion to rapid analogues, whose cross­reactivity has not 
been studied at all, and the glargine metabolites whose 
cross­reactivity has only been assessed with very few 
assays [14, 15]. Four insulin analogue concentrations were 
analysed ranging from 10 to 200 mU/L in PBS­1% BSA (or 
60–1200 pmol/L for glargine metabolites) to determine 
their cross­reactivity with human insulin as a function of 
concentration.
Materials and methods
Insulin, insulin analogues and metabolites
The structure and activity of insulin analogues are presented in 
the Supplemental Data Table S1, which accompanies the article at 
http://www.degruyter.com/view/j/cclm.2014.52.issue­3/issue­files/
cclm.2014.52.issue­3.xml. Human recombinant insulin (Actrapid 100 
IU/mL), aspart (Novorapid 100 U/mL) and detemir (Levemir 100 U/mL) 
were obtained from Novo Nordisk (Puteaux, France), lispro (Humalog 
100 U/mL) from Lilly (Suresnes, France), glargine (Lantus 100 U/mL) 
and glulisine (Apidra 100 U/mL) from Sanofi­Aventis (Paris, France). 
M1 and M2 (glargine metabolites) were kind gifts from Sanofi­Aventis 
(Professor J. Sandow, Frankfurt, Germany).
Insulin assays
The characteristics of the commercially available insulin assays are 
described in the Supplemental Data, Table S2. Assays were kind gifts 
of Abbott Diagnostics (Insulin Architect; Rungis, France), Beckman 
Coulter France (Ultrasensitive Insulin Access and Insulin IRMA kit; 
Roissy, France), DIAsource Europe S.A. (INS­EASIA and INS­IRMA; 
Nivelles, Belgium), CIS Bio (Insulin­CT and Bi­insulin IRMA; Gif­
sur­Yvette, France), DiaSorin (Liaison Insulin, INSI CTK­IRMA and 
INSIK­5; Antony, France), PerkinElmer (Wallac AutoDELFIA insulin; 
Villebon­sur­Yvette, France), Roche Diagnostics (Insulin Elecsys; 
Meylan, France), Siemens (Advia Centaur Insulin – IRI, Coat­A­Count 
Insulin; Puteaux, France), Tosoh (ST­AIA­PACK IRI, Lyon, France). 
Human insulin­specific RIA kit was purchased (Millipore, Saint 
Charles, USA).
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Samples
Insulin analogues contained in pen treatment units, and glargine 
metabolites were successively diluted in PBS­1% BSA to final concen­
trations of 10, 30, 100, and 200 mU/L, and 60, 180, 600 and 1200 
pmol/L, respectively, using a semi­automated diluter (Microlab 500, 
Hamilton, Reno, USA). The dilution steps of the stock solutions were 
validated by using a 125I­labelled solution. Each dilution point was 
prepared three times.
In order to study the influence of insulin analogues and glar­
gine metabolites on human insulin measurement they were mixed 
at a final concentration of 100 mU/L and 600 pmol/L, respectively, 
with recombinant insulin (final concentration of 100 mIU/L) in PBS­
1% BSA (data not shown).
Matrix
As glargin is metabolised by enzymes such as carboxypeptidases 
present in serum or plasma, the former were replaced by protein­
supplemented PBS for the assays. We consequently tested differ­
ent BSA concentrations ranging from 1% to 8% in PBS, in absence 
of insulin with 17 assays (data not shown). The Immulite assay was 
initially part of the study, but the results were not included in our 
paper, because the matrix alone (PBS­BSA without analogue or insu­
lin) surprisingly displayed results between 19 mIU/L and 41 mIU/L for 
BSA concentrations between 1% and 8%. That matrix was clearly not 
suitable to study Immulite. We did not observe such inconsistencies 
with the other assays whatever the BSA concentration and PBS­BSA 
1% has been retained.
Statistics
In order to test the validity of the different assays, linearity tests were 
performed according to the method previously described [23]. When 
significant, the test on departure from linearity leads to the rejection 
of the linearity assumption. A p­value less than 0.05 was considered 
as significant and indicated lack of linearity throughout the range of 
different concentrations. Computations were run with R 2.14″.
Results
Table 1 represents the cross­reactivity values obtained, for 
analogues and metabolites, as a function of the molecules 
assessed and their concentrations, with 16 immunoassays. 
The percentage of cross­reactivity was calculated from the 
ratio of the measured and nominal concentrations. The 
details of the methods used by the assays (type, principle, 
category, antibodies…) are described in the Supplemental 
Data, Table S2. These assays cover the most frequently 
used assays in the field and the various methods: auto­
mated or manual as well as two­site immunometric or 
competition assays. As a pre­requisite, we show that most 
commercial insulin assays (10/16) quantitatively detected 
human recombinant insulin (Actrapid®) whatever the 
concentrations between 10 and 200 mIU/L (Supplemen­
tal Data, Table S3). The source of discrepancies in results 
among commercial methods of insulin immunoassays 
is likely multifactorial and not explainable by a single 
analytical performance characteristic [4]. Matrix effects 
in combination with the fact that insulin assays are still 
calling for standardisation can explain this result [4, 24].
Insulin analogues
We studied three short­acting and two long­acting insulin 
analogues using the same 16 commercial assays (Table 1 
and Supplemental Data, Table S1). The cross­reactivity 
values were comprised between 0% and 264% as a func­
tion of the analogues. A similar scale was also observed for 
a single analogue, i.e., detemir, yielding cross­reactivity 
values between 0% and 264% as a function of the assays 
used. Furthermore, let us note that four assays (Elecsys 
Roche, Diasorin Liaison, Ins­IRMA Beckman and Wallac 
AutoDELFIA PerkinElmer) showed a high specificity to 
human insulin, with no or little cross­reactivity whatever 
the analogue studied.
Glargine metabolites
Insulin glargine is a long­acting human insulin analogue. 
Following subcutaneous administration insulin glargine 
precipitates. Proteolytic degradation results in two main 
active metabolites: M1 and M2, formed by the sequential 
removal of the two arginines from the carboxy­terminus 
of the B­chain and additional deamination of threonine 
in position B30 [25, 26]. Their similarity with the human 
insulin structure led to check their cross­reactivity. As 
with analogues, the performance of the various commer­
cial assays was not uniform with respect to cross­reactivity 
with both glargine metabolites. Cross­reactivity was close 
to 100% in five immunoassays, and at least two others 
displayed cross­reactivity values  < 5%. In general, a given 
assay yielded similar cross­reactivity values for the two 
metabolites, except for Elecsys, which presented cross­
reactivity for M1 around 22% but none for M2.
Influence of concentration
Table 1 details the effect of analogue concentration 
(between 10 and 200 mU/L) and metabolite concentration 
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Table 1 Cross-reactivities (%) of insulin analogues and two metabolites of glargine.
Concentration, 
mU/L
 
 
 
Analogues   
 
 
Glargine metabolites
Short action  
 
Long action Concentration, pmol/L   M1   M2
Lispro   Aspart   Glulisine Glargine   Detemir
Access (Beckman)
10   87   92   0.3   110   9   60   130   130
30   89   91   0.9   106   12   180   120   120
100   91   93   4.9   100   21   600   109   109
200   93   93   10.7   95   26   1200   104   104
Advia Centaur IRI (Siemens)
10   99   143   8   137   32   60   120   139
30   97   138   3   135   28   180   117   141
100   101   148   2   154   27   600   129   138
200   115    > 150   2    > 144   27   1200   128   143
Architect (Abbott Laboratories)
10   85   61    < 10   110   52   60   123   118
30   83   62   4.9   108   60   180   116   113
100   87   67   7   108   87   600   114   109
200   86   71   8.9   106   98   1200   109   104
Wallac AutoDELFIA Insulin (PerkinElmer)
10    < 5    < 7.3    < 5    < 5    < 5   60    < 5    < 5
30    < 1.7    < 1.7    < 1.7   5    < 1.7   180   4    < 1.7
100    < 0.5    < 0.5    < 0.5   12    < 0.5   600   10    < 0.5
200    < 0.25    < 0.25    < 0.25   18    < 0.25   1200   16    < 0.25
Bi-insulin IRMA (CIS Bio)
10   97   95    < 2   115   230   60   116   114
30   107   104    < 1   126   239   180   130   126
100   103   101   2   117   221   600   119   116
200   98   101   3   115   212   1200   113   112
Cobas/Elecsys (Roche Diagnostics)
10    < 2    < 2    < 2    < 2    < 2   60   23    < 2
30    < 0.7    < 0.7    < 0.7    < 0.7    < 0.7   180   22    < 0.7
100    < 0.2    < 0.2    < 0.2    < 0.2    < 0.2   600   21    < 0.25
200    < 0.1    < 0.1    < 0.1    < 0.1   0.1   1200   21   0.1
Coat-A-Count (Siemens)
10    < 50    < 50    < 50    < 50    < 50   60    < 50    < 50
30   48   42    < 17    < 17    < 17   180    < 17    < 17
100   54   50   7   8   7   600   6   7
200   48   45   10   7   7   1200   6   6
Human insulin Specific RIA (Millipore)
10   114   85   64   155   44   60   104   111
30   96   68   54   164   37   180   100   94
100   81   55   48   159   33   600   101   82
200   73   51   47    > 94   30   1200    > 77   72
Ins-EASIA (DIAsource)
10   76   74   80   86   67   60   123   92
30   27   33   26   32   17   180   38   25
100   8   7   8   20   7   600   16   10
200   6   4   6   19   5   1200   13   6
Ins-IRMA (Immunotech Beckman)
10    < 5    < 5    < 5    < 5    < 5.6   60    < 5    < 5
30    < 1.7    < 1.7    < 1.7   3    < 1.9   180    < 2.6    < 2.30
100    < 0.5    < 0.5    < 0.5   7    < 0.5   600   4    < 0.7
200    < 0.25    < 0.28    < 0.25   13    < 0.26   1200   8   0
INSI-CTK IRMA (DiaSorin)
10   97   109    < 4   22   105   60    < 35    < 17
30   92   105    < 1   12   115   180   23   24
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(between 60 and 1200 pmol/L) on cross­reactivity values. 
Cross­reactivity increased or more frequently decreased 
as a function of concentration. Indeed the DIAsource 
INS­IRMA assay could detect analogues with around 65% 
cross­reactivity when their concentrations were around 
10  mU/L, but cross­reactivity gradually decreased as a 
function of concentration, down to 3% at 200 mU/L. Sta­
tistical analysis allowed to highlight the cross­reactivity 
results that varied linearly as a function of concentration 
(Supplemental Data, Figure S1). Cross­reactivity was linear 
in 58% of the immunoassays (65/112), and some immuno­
assays yielded predominantly linear results whatever the 
analogue, i.e., Ins­EASIA, DIAsource and Insulin­CT, Cis 
Bio. The linearity could not be correlated with the insulin 
analogue or the immunoassay methods used. Analogue 
concentration appears to be an important parameter to 
take into account in the choice of the insulin assay to 
be used. In some cases, statistical analysis of the results 
obtained with some analogues was not possible when 
those were under the method detection threshold (italic 
font in Table 1) (26/112). However, despite of the lack of 
statistical analysis, one can conclude that these methods 
are not suitable for the detection of these analogues.
Discussion
The aim of the current study was to highlight and measure 
with commonly used immunoassays the possible cross­
reactivity of various analogues. All the measurements 
were performed in the presence of albumin to limit the 
adsorption of analogues to plastic­ware occurring in the 
absence of protein, thus diminishing the amount avail­
able for detection by the assays [27].
In our work, the study of the analogues showed that 
four assays were specific to human insulin, resulting in 
negligible cross­reactivity with the analogues while yield­
ing values  > 90% for human insulin. Cross­reactivity is a 
function of the binding of the antibodies employed in the 
assay. Human insulin has antigenic determinants differing 
Concentration, 
mU/L
 
 
 
Analogues   
 
 
Glargine metabolites
Short action  
 
Long action Concentration, pmol/L   M1   M2
Lispro   Aspart   Glulisine Glargine   Detemir
100   99   106    < 0.9   16   125   600   36   29
200    > 93    > 100    < 0.15   16    > 100   1200   39   42
INSIK-5 (DiaSorin)
10   49   64   42    < 55   71   60   46   44
30   62   65   37   44   52   180   57   49
100   57   63   22   29   28   600   49   40
200   49   55   15   23   18   1200   38   34
Insulin-CT (Cis Bio)
10   89   80   95   59   172   60   105   78
30   95   104   90   76   220   180   99   101
100   103   109   81   85   264   600   95   103
200   110   118   71   83    > 155   1200   90   94
INS-IRMA (DIAsource)
10   66   64   65   79   62   60   70   65
30   22   22   23   47   22   180   35   23
100   7   7   7   48   6   600   30   9
200   3   3   3   51   3   1200   32   7
Liaison (DiaSorin)
10    < 2    < 2    < 2    < 6    < 2   60    < 2    < 2
30    < 0.7    < 0.7    < 0.7   6    < 0.7   180   7    < 0.7
100    < 0.2    < 0.2    < 0.2   18    < 0.2   600   17    < 1
200    < 0.1    < 0.1    < 0.1   29    < 0.1   1200   27    < 0.8
ST AIA-PACK IRI (Tosoh)
10   106   122   63   16   58   60   43   63
30   109   124   67   20   60   180   50   70
100   113   126   78   36   72   600   74   84
200   112   121   79   50   76   1200   84   98
Absence of statistical analysis owing to values under the detection threshold of the method: italic font type.
(Table 1 Continued)
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from the antigenic sites of insulin analogues. One of them 
is comprised between the positions 27–30 of the B­chain 
[28] and the other concerns the residues 8–10 of the A­chain 
[29, 30]. Considering the structure of the studied analogues 
(Supplemental Data, Table S1), the results suggest that at 
least these four assays are based on the use of antibod­
ies recognising the C­terminal part of the B­chain, which 
is altered within the sequence of the analogues studied, 
hence the lack of or very low cross­reactivity. These results 
confirm and extend the scope of the lack of cross­reactivity 
reported in 2001 using the Elecsys method applied to lispro 
measurements [21]. In the same way, the difference in 
cross­reactivity between the glargine metabolites (M1 and 
M2) using the Elecsys assay can be explained by the struc­
ture of M1, with a conserved B­chain maintaining recogni­
tion by antibodies directed against the C­terminal part of 
the B­chain and probably used in the Elecsys method. M2 
is not recognised owing to the alteration of the C­terminal 
part of the B­chain. It is of prime importance to discrimi­
nate glargine from its metabolites. Indeed, we henceforth 
know that after injection, glargine is minimally detectable 
in blood due to its rapid conversion into M1 and M2 metabo­
lites. A relation between glargine administration and a risk 
of cancer was assumed partly due to in vitro studies but 
this relation is challenged [31]. Pierre­Eugène et al. showed 
that pro­mitogenic properties of glargine in cultured cells 
should be abrogated in vivo by its rapid conversion into 
metabolites [32]. Recent studies on type 1 and 2 diabetic 
subjects showed that the long­acting metabolic effects are 
related to the main metabolite M1 [33, 34] reinforcing the 
importance of its specific detection and quantification.
The effect of the primary ligand (human insulin in our 
study) on the degree of observed cross­reactivity has been 
previously described. According to Miller and Valdes, 
depending on the assay, human insulin may moderately 
decrease or increase cross­reactivity with insulin ana­
logues [35, 36]. In our work, the simultaneous presence of 
the primary ligand (human insulin) and of the cross­reac­
tant have miscellaneous effects depending on the assay 
and on the analogue assessed (data not shown).
The various immunoassays used were either two­site 
specific immunometric or competitive assays (Supplemen­
tal Data, Table S2). We can note in Table 1 that competitive 
assays (Coat­A­Count, Siemens; Human Insulin Specific 
RIA, Millipore; INSIK­5, DiaSorin; Insulin­CT, Cis Bio) were 
able to detect all the analogues and metabolites resulting 
in non­negligible cross­reactivity. As a consequence, these 
four methods do not appear in the last column of Table 
2, which highlights methods without cross­reactivity 
with any analogue or metabolite. This result is consist­
ent with the fact that the polyclonal antibodies used for 
competitive assays provide lesser specificity compared to 
monoclonal antibodies.
In competitive immunoassays using polyclonal anti­
bodies (e.g., Human insulin specific RIA and INSIK­5), the 
decrease in measured cross­reactivity as the concentration 
of cross­reactant increases has already been described by 
Miller and Valdes [35, 36]. In a polyclonal antiserum, mul­
tiple antibodies display varying affinities for the primary 
antigen. 
Sets of antibodies with low affinity for the standard 
antigen may have a high affinity for the cross­reactant. 
The first small amounts of cross­reactant easily displace 
bound label from these less specific antibodies. As the 
cross­reactant saturates the less specific antibodies, addi­
tional amounts of cross­reactant are less likely to displace 
bound label from the more specific antibodies. Owen et al. 
had previously studied the cross­reactivity of three recom­
binant insulin analogues (insulin aspart, glargine, insulin 
lispro) with five commercial insulin immunoassays in the 
presence of BSA. The large variability in the degree of cross­
reactivity of those analogues with the five different commer­
cial assays is noteworthy [13]. We have reached the same 
conclusion, i.e., that of a large variability in cross­reactivity 
through the extensive study of five insulin analogues and 
two metabolites using 16 immunoassays. Table 2 summa­
rises the specific assay(s) that can be used ( > 90% cross­
reactivity) as well as the commercial assays without any 
cross­reactivity ( < 5%) for each analogue. It shows that few 
methods allow the detection of glulisine, but for one with 
cross­reactivity around 90% (Insulin­CT, CisBio). For every 
other analogue, there is at least one available assay able to 
detect the molecule with high cross­reactivity (90%–110%). 
As a consequence, when secret insulin administration is 
suspected one of the four human insulin­specific assays 
should be used in parallel with a second insulin assay 
presenting  significant cross­reactivity with insulin ana­
logues. Krull et al. [15] have shown the benefit of knowing 
the capacity of individual assays to measure or not insulin 
analogues. In their work, they evidenced a case of facti­
tious hypoglycaemia by self­administration of lispro and 
glargine, thanks to the complementary use of both Elecsys® 
and Advia Centaur® assays and their discordant results [15].
This work shows that insulin immunoassays have 
various degrees of cross­reactivity with insulin analogues 
and their metabolites. However, knowing that kit manu­
facturers may change lots of reagent antibodies (mainly 
for polyclonal antibodies) [37] sometimes without commu­
nicating such changes to laboratory users, we therefore do 
recommend the use of specific in­house quality controls 
(i.e., samples with analogue dilutions) to validate new 
kit lots before assessing insulin analogues. Nevertheless, 
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this study brings a very useful comparison of immunoas­
says available to clinicians when they must discriminate 
between insulin of various origins.
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